DRI Healthcare agrees to buy tavapadon royalty rights for US$316 million upon FDA approval
DRI Healthcare Trust agreed to buy U.S. royalty participation rights on Parkinson’s candidate tavapadon for USD 316 million. Closing is contingent on FDA approval, expected in Q3 2026, along with other customary conditions. Deal includes tiered royalties on annual U.S. net sales at mid-single digit to low-double digit